GSK acquire Cellzome for £61 million

The Telegraph have reported that GSK  today, announced that it has entered an agreement to acquire Cellzome for £61 million in which they already own a 20pc stake.

Cellzome is the leader in the development and advancement of proteomics technologies. It currently has labs in Cambridge in the UK and Heidelberg in Germany. GSK currently own 19.98 % equity in the company but they will now assume full control of Cellzome. It will become part of GSK’s R&D organisation.

John Baldoni, senior vice-president of Platform & Technology Science at Glaxo, said: “The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterise drug targets, and provides the opportunity to further enhance Glaxo’s ability to bring medicines to patients in a more effective manner.”

Looking for a job in science?

Click here to search our current jobs in science now.

Posted in: Industry News, News
CK Logo in place of featured image